(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 August 2025 (28.08.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/176999 A2

(51) International Patent Classification:
C07K 14/605 (2006.01) *A61P 9/10* (2006.01)
C07K 14/575 (2006.01) *A61P 25/28* (2006.01)
A61P 3/04 (2006.01) *A61K 38/00* (2006.01)
A61P 3/10 (2006.01)

(21) International Application Number:
PCT/GB2025/050341

(22) International Filing Date:
21 February 2025 (21.02.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/GB2024/050504
23 February 2024 (23.02.2024) GB

(71) Applicant: **IP2IPO INNOVATIONS LIMITED** [GB/GB]; 2nd Floor, 3 Pancras Square, King's Cross, London N1C 4AG (GB).

(72) Inventor: **BLOOM, Stephen Robert**; c/o Imperial College of Science, Technology, and Medicine, Exhibition Road, London SW7 2AZ (GB).

(74) Agent: **ABEL & IMRAY LLP**; Westpoint Building, James Street West, Bath Bath and North East Somerset BA1 2DA (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: NOVEL COMPOUNDS

Figure 1

Ex	GIP ref	SEQ ID	Note	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34
1	A	10		Tyr	AIB	Glu	Gly	Thr	Phe	Ile	Ser	Asp	Tyr	Ser	Lys	Asp	Leu	Asp	Lys	Ile	His	Gln	Gln	Asp	Phe	Val	Asn	Trp	Leu	Leu	Ala	Gln	Lys	Gly	Lys		Lys*
2	B	11		Tyr	AIB	Glu	Gly	Thr	Phe	Ile	Ser	Asp	Tyr	Ser	Lys	Ala	Leu	Asp	Lys	Ile	His	Gln	Gln	Asp	Phe	Val	Asn	Trp	Leu	Leu	Ala	Gln	Lys	Gly	Lys		Lys*
3	C	12		Tyr	AIB	Glu	Gly	Thr	Phe	Ser	Ser	Asp	Tyr	Ser	Lys	Asp	Leu	Asp	Lys	Ile	His	Gln	Gln	Asp	Phe	Val	Asn	Trp	Leu	Leu	Ala	Gln	Lys	Gly	Lys		Lys*

(57) Abstract: The invention provides novel compounds which are peptide hormone analogues, and which are useful in treating disorders such as diabetes and obesity. The compounds of the general sequence recited in the specification possess a tailored profile with regards to potency properties at the GIP receptor. With regard to in vivo properties, administration of example peptides of the invention have been shown, in animal models, to result in increased weight loss. Preferred compounds achieve this without reducing food intake significantly.

WO 2025/176999 A2